Table 4.
Risk of specific infectious complications and suggested prevention strategies.
| Agent | Risk of HSV/VZV | Risk of PJP | Risk of HBV Reactivation | Risk of CMV Infection | Other Risk |
|---|---|---|---|---|---|
| Rituximab | Low | Low | Yes | Low | PML; Respiratory tract infections |
| GO | N/A (AML patients receive prophylaxis) | ||||
| Pembrolizumab | Only after irAEs | No | Yes | Only after irAEs | LTBI |
| Blinatumomab | Yes | Yes | Yes | Low | PML; HGG |
| Imatinib | Low | No | Yes | Low | |
| Dasatinib | Yes | No | Yes | Yes | |
| Nilotinib | Low | No | Yes | Low | |
| Tisagenlecleucel | Yes/Low | Yes | Yes | Yes | HGG; after CRS |
| InO | No | Low | Low | No | |
| BV | N/A (HSCT recipients receive prophylaxis) | N/A (HSCT recipients receive prophylaxis) | Yes | Yes | PML |
| Bortezomib | Low/Yes | Low | Low | Low | Respiratory tract infections |
| Venetoclax | No | No | No | No | |
N/A = not available data.